According to the neurovascular hypothesis, impairment of low-density lipoprotein receptorrelated protein-1 (LRP1) in brain capillaries of the blood-brain barrier (BBB) contributes to neurotoxic amyloid-b (Ab) brain accumulation and drives Alzheimer's disease (AD) pathology. However, due to conflicting reports on the involvement of LRP1 in Ab transport and the expression of LRP1 in brain endothelium, the role of LRP1 at the BBB is uncertain. As global Lrp1 deletion in mice is lethal, appropriate models to study the function of LRP1 are lacking. Moreover, the relevance of systemic Ab clearance to AD pathology remains unclear, as no BBB-specific knockout models have been available. Here, we developed transgenic mouse strains that allow for tamoxifen-inducible deletion of Lrp1 specifically within brain endothelial cells (Slco1c1-CreER T2 Lrp1 fl/fl mice) and used these mice to accurately evaluate LRP1-mediated Ab BBB clearance in vivo. Selective deletion of Lrp1 in the brain endothelium of C57BL/6 mice strongly reduced brain efflux of injected [ 125 I] Ab 1-42 . Additionally, in the 5xFAD mouse model of AD, brain endothelial-specific Lrp1 deletion reduced plasma Ab levels and elevated soluble brain Ab, leading to aggravated spatial learning and memory deficits, thus emphasizing the importance of systemic Ab elimination via the BBB. Together, our results suggest that receptor-mediated Ab BBB clearance may be a potential target for treatment and prevention of Ab brain accumulation in AD.
Introduction
Accumulation of amyloid-β (Aβ) in the brain is a key event in Alzheimer's disease (AD) pathogenesis. Recent evidence suggests that in the common sporadic or late-onset forms of AD and in some cases of familiar AD (FAD) elevated Aβ brain levels result from impaired clearance instead of overproduction (1) . The most prominent variants of Aβ consist of the first 40 (Aβ ) and 42 (Aβ ) amino acids, respectively. The two additional hydrophobic amino acids of Aβ 1-42 generate a more aggregation-prone and neurotoxic peptide (2) . Low Aβ levels within the healthy brain are maintained through degradation, elimination via interstitial fluid (ISF) bulk flow, cerebrospinal fluid (CSF) absorption into the circulatory and lymphatic system, or transport across the blood-brain barrier (BBB) (3, 4) . Cell-surface receptor low-density lipoprotein receptor-related protein-1 (LRP1) has been reported to be involved not only in Aβ endocytosis and cerebral degradation (5-7), but also in Aβ transcytosis through the brain endothelium and subsequent systemic elimination via liver, spleen, and kidneys (8) .
Aging is the most prominent risk factor for AD. LRP1 expression decreases in total brain and brain capillaries with age (8, 9) . Moreover, LRP1 is further reduced in AD (8, 10) . Additionally, highly validated genetic risk factors for AD, like the apolipoprotein E (apoE) Ε4 allele or the gene encoding the phosphatidylinositol-binding clathrin assembly (PICALM), are believed to be linked to reduced clearance of Aβ via LRP1 (11) (12) (13) . In senile plaques, LRP1 ligands, like apoE, urokinase-type plasminogen activator, tissue plasminogen activator, and lactoferrin, co-deposit with Aβ, all together indicating a loss of LRP1 function in AD (14) . Recent studies suggest that transport across the BBB is a major elimination route for brain Aβ (8, 11, 12, 15) . Thus, the neurovascular hypothesis of AD states that Aβ accumulation is driven by impairment of Aβ transporters in brain capillaries, resulting in deficient Aβ elimination via the BBB (3, 8, 15, 16) .
However, there are conflicting studies showing no or little contribution of LRP1 to Aβ clearance across the BBB (5, (17) (18) (19) (20) . Due to the lack of appropriate model systems, the role of LRP1 at the BBB and the overall relevance of BBB clearance are insufficiently understood and debated (4, 7) . Many Aβ clearance studies make use of LRP1 inhibition through injected antibodies or low-density lipoprotein receptor (LDLR) family antagonists; however, this approach does not allow the specific inhibition of the BBB clearance pathway (21) . Global Lrp1 knockout mice are embryonically lethal (22, 23) . Until now, no animal model had been available to study the role of LRP1 at the BBB. Using a brain endothelialspecific Cre-expressing mouse line (24) , we generated what we According to the neurovascular hypothesis, impairment of low-density lipoprotein receptor-related protein-1 (LRP1) in brain capillaries of the blood-brain barrier (BBB) contributes to neurotoxic amyloid-β (Aβ) brain accumulation and drives Alzheimer's disease (AD) pathology. However, due to conflicting reports on the involvement of LRP1 in Aβ transport and the expression of LRP1 in brain endothelium, the role of LRP1 at the BBB is uncertain. As global Lrp1 deletion in mice is lethal, appropriate models to study the function of LRP1 are lacking. Moreover, the relevance of systemic Aβ clearance to AD pathology remains unclear, as no BBB-specific knockout models have been available. Here, we developed transgenic mouse strains that allow for tamoxifen-inducible deletion of Lrp1 specifically within brain endothelial cells (Slco1c1-CreER T2 Lrp1
fl/fl mice) and used these mice to accurately evaluate LRP1-mediated Aβ BBB clearance in vivo. Selective deletion of Lrp1 in the brain endothelium of C57BL/6 mice strongly reduced brain efflux of injected [
125 I] Aβ . Additionally, in the 5xFAD mouse model of AD, brain endothelial-specific Lrp1 deletion reduced plasma Aβ levels and elevated soluble brain Aβ, leading to aggravated spatial learning and memory deficits, thus emphasizing the importance of systemic Aβ elimination via the BBB. Together, our results suggest that receptor-mediated Aβ BBB clearance may be a potential target for treatment and prevention of Aβ brain accumulation in AD.
Endothelial LRP1 transports amyloid-β 1-42 across the blood-brain barrier in both groups of mice ( Figure 3C ). CD11b-positive cells away from vessel-shaped structures in both groups of mice showed little colocalization, consistent with previous findings showing weak expression of LRP1 in some glial cells only (27, (29) (30) (31) . Primary microglia, neurons, and astrocytes isolated from adult Lrp1 BE -/-mice showed abundant LRP1 expression after tamoxifen induction (Supplemental Figure 4) . We could not see any effects on the in vivo BBB permeability due to the knockout of Lrp1 in endothelial cells. Brain permeability for IgG and the low-molecular-weight marker Na-fluorescein did not show differences between genotypes, indicating an intact BBB in vivo (Figure 4) .
Deletion of Lrp1 in brain endothelium results in reduced [
125 I] Aβ transcytosis in vitro. Previously, we have shown that primary brain endothelial cells with inactive LRP1 harboring an NPxYxxL mutation in the endocytosis motif transcytosed significantly less Aβ than WT cells (32) . Moreover, several in vivo studies have suggested that LRP1 is involved in Aβ clearance across the BBB (8, 11, 12, 15, 21, 33) . However, other studies have failed to see a LRP1 contribution to Aβ BBB clearance in various models (5, (17) (18) (19) . To understand the discrepancies between previous works, we studied Aβ transport across a Lrp1-deficient brain endothelial monolayer in a standard model (5, 32, 34 Figure 5A ). Then, we investigated a range of different physiologically relevant Aβ concentrations to validate our findings. We used Aβ concentrations ranging from 0.05 nM, normally found in plasma of healthy individuals (15) , to 5 nM, corresponding to elevated Aβ levels in brains of patients with AD and AD animal models (15 Deletion of Lrp1 in brain endothelium impairs Aβ efflux from brain. After verification of LRP1-mediated Aβ transcytosis, we aimed to study the role of endothelial LRP1 in vivo with the brain efflux index method (8, 11, 12, 15 Figure 1A and Supplemental Figures 2 and 3) . Likewise, analysis of lysates revealed the absence of the protein in brain endothelial cells of Lrp1 BE -/-mice ( Figure 1B ). Full Lrp1 deletion was also confirmed via PCR analysis (26) on the genomic level ( Figure 1C ). Having shown full deletion of Lrp1 in brain endothelium of Lrp1 BE -/-mice, we wanted to verify brain endothelial-specific Cre activity, as reported for Slco1c1-CreER T2 mice (24) . A closer look at the vasculature revealed that CD31-negative cells adjacent to the endothelium that make up the neurovascular unit were positive for LRP1 in Lrp1 BE -/-mice ( Figure 1A and Supplemental Figure 3) , showing brain endothelial-specific expression of Cre recombinase and no leakage of Cre recombinase in surrounding cells. In both groups, cells surrounding the vasculature showed widespread expression of LRP1. Ubiquitous expression for LRP1 throughout the brain has been reported previously (27) . Next, we determined LRP1 abundance in capillary-depleted brain fractions of Lrp1 BE -/-and Lrp1 BE fl/fl mice with different LRP1 antibodies. Neither with the monoclonal N-terminal 11E2 (Supplemental Figure 2) nor with the well-described polyclonal C-terminal antibody 1704 could we see differences in Lrp1 expression in brain tissue deprived of capillaries ( Figure 2 ). Moreover, we detected LRP1 and different cell markers in cortical brain sections of these mice. NeuNpositive neurons showed strong LRP1 expression in the soma of neurons ( Figure 3A) , validating high LRP1 expression in neuronal cell bodies as reported previously (28, 29) . In addition, the vast majority of glial fibrillary acidic protein-positive (GFAPpositive) astrocytes in Lrp1 BE -/-mice were LRP1 positive (Figure 3B) . Little recombination in 7% of astrocytes for this mouse line has been reported before (24) . With anti-LRP1 11E2 and a marker for microglia and macrophages (anti-CD11b), we showed costaining of LRP1 and CD11b around vessel-shaped structures fl/fl ), stressing the importance of endothelial LRP1 in rapid Aβ clearance. Interestingly, 30 minutes after CNS injection, Aβ brain retention in both groups approximated a respective plateau, with reduction (about 44%) of Aβ brain retention in brains of Lrp1 BE fl/fl animals, even 3 hours after injection of these small amounts of tracers ( Figure 6A ). This suggested that approximately 44% of the low nM Aβ pool in mice still present after 3 hours could only be cleared when LRP1 was present in brain endothelium.
To investigate the importance of LRP1 on BBB Aβ clearance in a well-established mouse AD model, we crossed the Lrp1 BE fl/fl mice with 5xFAD mice. These mice express 5 FAD mutations under Thy-1 promotor control to increase overall Aβ 1-42 production in the brain (37) . Through deletion of brain endothelial Lrp1 in 5xFAD mice we could study Aβ transport without the need to inject radiolabeled peptides. ]-inulin was cleared in a slow, passive, and equal manner in both groups, demonstrating an intact BBB ( Figure 6B ). Importantly, both tracers were hardly detectable in CSF, with no differences among the groups ( Figure 6 , D and E). This implicated that the low concentrations of Aβ injected into the caudate putamen were mostly eliminated by rapid clearance across the microvessels and not by clearance from the ISF into the CSF. The amounts of tracers found in the plasma were low due to rapid systemic body clearance (8 (Figure 9 ), suggesting that LRP1 preferentially clears Aβ , even when Aβ 1-42 is of higher abundance. Additionally, the plasma Aβ 1-42 /Aβ 1-40 ratios in 5xFAD Lrp1 BE fl/fl animals were lowered by about the same fold ( Figure 9 ). This demonstrates that LRP1 preferentially binds Aβ 1-40 when available, confirming previous findings showing a differential affinity of LRP1 to the two Aβ variants (15) .
Brain endothelial LRP1 deficiency exacerbates Aβ-dependent cognitive deficits. Next, we investigated how brain endothelial LRP1 deficiency affects AD-related behavior by examining spatial learning and memory (40, 41) . We used three different tests to examine motor deficits, string suspension, inverted grip, and balance beam, and found that no mice in any tested group showed abnormalities (Supplemental Figure 6 ). The ability of vision of the mice was tested by visual placing (42) before mice entered the Morris water maze. The Morris water maze is a particularly sensitive test to examine age-related memory impairments in AD mice. Previously, it has been shown that 5xFAD mice display AD-like memory deficits at 12 months of age (43) . Same-aged WT mice, however, did not show these deficits. As we saw that knockout of Lrp1 in the brain cerebrovasculature of 5xFAD mice severely elevated the soluble brain Aβ levels, we investigated whether 5xFAD Lrp1 BE fl/fl mice displayed memory deficits early and examined spatial learning and memory at 7 months of age. Spatial learning tests in 5xFAD Lrp1 BE -/-mice after acquisition training showed significantly higher escape latencies on days 3, 4, and 5 compared with those of the rest of the groups ( Figure 10A ). Swimming speeds did not differ among groups ( Figure 10B ). These results suggest that spatial learning is impaired in 5xFAD Lrp1 BE -/-mice. The probe trial for monitoring spatial reference memory revealed that 3 of 4 groups, including 5xFAD Lrp1 BE fl/fl mice, displayed a significant preference for the target quadrant, whereas no quadrant preference was found for 5xFAD Lrp1 BE -/-mice ( Figure 10 , C and D). Swimming speeds did not differ among groups ( Figure 10E ). In summary, the results illustrated that endothelial-specific Lrp1 knockout in 5xFAD mice and, therefore, reduced clearance of Aβ peptides induced an impairment of both spatial learning and spatial reference memory.
We determined Aβ efflux and brain retention in 7-monthold 5xFAD Lrp1 BE fl/fl and 5xFAD
mice showed reduced plasma levels of both Aβ 1-40 and Aβ 1-42 associated with reduced Aβ transport out of the brain ( Figure  7 , A, D, and E). In line with these data, we found significantly higher levels of soluble Aβ in 5xFAD Lrp1 BE -/-brains, consistent with impaired transport of Aβ out of the brain ( Figure  7 , B, F, and G). Soluble Aβ levels were elevated about 2.5-fold for Aβ and about 3.7-fold for Aβ in 5xFAD Lrp1 BE -/-mice. Insoluble Aβ 1-42 levels showed a trend toward higher levels in 5xFAD Lrp1 BE -/-mice, with higher variations in individual mice ( Figure 7 , C, H, and I). Therefore, we determined the absolute Aβ levels in 5xFAD Lrp1 BE -/-mice and littermates via ELISA. Reflecting the immunoprecipitation data, 7-month-old 5xFAD mice had significantly higher soluble Aβ levels (approximately 4.8-fold for Aβ x-40 and 3.1-fold for Aβ x-42 ) and insoluble Aβ x-40 levels (approximately 2.0-fold change) when LRP1 was absent in brain endothelium ( Figure 7 , L and M). Again, there was a trend toward higher insoluble Aβ x-42 levels that did not reach statistical significance ( Figure 7L ). Plaque load quantification mirrored the data collected from prior measurements and showed no significant difference in plaque load in the hippocampus (Figure 7 , J and K), cortex, or subiculum (Supplemental Figure 5) . In AD, activated astrocytes and microglia play an important role in clearing Aβ deposits by triggering phagocytic uptake (38, 39) . Both AD models showed reactive astrocytes and microglia in the hippocampus (Figure 8 ). However, we found no significant difference in Iba1 or GFAP immunoreactivity between 5xFAD Lrp1 BE -/-and 5xFAD Lrp1 BE fl/fl mice. All together, the collected data from two different in vivo models indicated that brain endothelial LRP1 substantially regulates the soluble brain Aβ levels and that LRP1-mediated transport across the BBB is a major pathway of Aβ clearance.
Differential binding affinity of LRP1 to Aβ (12, 13) . However, controversial findings from different groups and the lack of appropriate models to study BBB transporters have created growing ambiguity in the field (8, 11, 12, 15, (17) (18) (19) 47) . Previous reports have shown no contribution for LRP1 to transcytosis of Aβ in different BBB models (5, 18, 19) , and research teams have doubted that the expression of Lrp1 in brain endothelium is sufficient to mediate substantial Aβ clearance (7, 28, 48, 49) . Here, with the first brain endothelial-specific Lrp1 knockout model to our knowledge, we show that LRP1 in brain endothelial cells is a key transporter mediating Aβ efflux out of the brain. Deletion of Lrp1 in brain endothelium in an AD mouse model enhances Aβ accumulation and leads to AD-related behavioral deficits. To our knowledge, Cre recombinase under the control of endothelial cell-specific promoters has not been used to address the role of brain endothelium in Aβ clearance. Previous studies have highlighted the importance of Aβ clearance by cellular degradation in neurons (6), astrocytes (39), microglia cells (38) , and vascular smooth muscle cells (7) . Numerous studies have tried to show the relevance of BBB contribution to Aβ clearance in vivo; however, they have failed to specifically inhibit brain vasculature LRP1 or have neglected the role of Aβ degradation within the brain (8, 11, 15, 33) . Here, for what we believe to be the first time, a BBB-specific knockout mouse was used to evaluate the relevance of Aβ BBB clearance via LRP1.
We studied whether clearance of AD pathology-driving Aβ 1-42 is affected in Lrp1 BE -/-mice. Using physiological Aβ concentrations, we observed that half of the BBB clearance is mediated by brain endothelial LRP1 in various model systems. In vivo, plasma Aβ levels in 5xFAD mice were significantly reduced and soluble brain levels were significantly elevated when LRP1 was absent in brain endothelium. When injecting low nM [ 125 I] Aβ 1-42 concentrations in mice, we found no significant amount of radioactivity in the CSF, showing that the small amounts of injected Aβ are rapidly cleared via the BBB and that a minor amount of injected Aβ is cleared via bulk flow as also observed by previous studies (8, 11, 12) . We found that approximately 48% of BBB transport is mediated by LRP1. This is in line with previous studies showing that Aβ brain efflux can be reduced to approximately 50% by coinjecting LRP1 antibodies or antagonists (8, 21) . Moreover, it has been shown that deletion of very LDLR (VDLDR) and LDLR genes did not significantly affect Aβ brain clearances, suggesting a minor importance of other LDL receptors in Aβ brain-to-blood transport (15) . Besides, our data collected from the 180-minute time point suggest that brain endothelial LRP1 is able to clear low nM Aβ pools that can only be cleared by the LRP1. Having shown that LRP1 in brain endothelium in vivo mediates approximately 27% of total Aβ clearance at pathophysiological levels, LRP1 at the BBB seems to be a key player in AD pathology. In addition, the in vitro transport studies revealed a substantial contribution of LRP1 in Aβ transcytosis. The data furthermore suggest that, at elevated Aβ concentrations, like during the progression of AD, the importance of Aβ clearance by fast endocytic receptor LRP1 is crucial. While, at picomolar concentrations, the contribution of LRP1-mediated clearance was 49.2% (0.1 nM Aβ), it increased with rising Aβ concentrations to 65.4% at 5 nM Aβ. This could be due to the high Aβ-binding capacity and the fast endocytosis rate of LRP1. It has been shown that, at 5 nM, Aβ binding to LRP1 is not yet saturated (50, 51) . Moreover, with an endocytosis rate up to 16 times faster than that of other Aβ receptors, such as VDLDR or LDLR (12, 35) , LRP1 may outperform other receptors in Aβ clearance, especially at higher concentrations. Additionally, in the 5xFAD mouse model, we could collect in vivo data on the importance of LRP1 in clearance at higher Aβ levels. Aβ brain levels in 5xFAD mice rise with age (37). In 7-month-old 5xFAD Lrp1 BE -/-animals, the plasma levels for both Aβ 1-40 and Aβ are strongly reduced and the brain levels highly elevated, each by more than 50%. This strong effect is probably not solely the result of deficient BBB and CSF-blood clearance in these animals but could also be due to the predominant importance of LRP1 at rising Aβ levels in aging animals. Previous studies have shown higher binding affinity of LRP1 to Aβ and faster clearance of this variant than of Aβ (11, 15) . We confirmed these findings in 5xFAD Lrp1 BE -/-mice in vivo. When measuring the Aβ 1-42 /Aβ 1-40 ratio in 5xFAD mice, we saw that both Aβ variants were cleared by LRP1 but noticed preferential clearance of Aβ . This binding affinity difference could lead to fatal consequences in patients. When LRP1 expression decreases during aging and in AD (8, 10) , fewer receptors will not only cause rising Aβ accumulation in the brain, but will preferentially clear less toxic Aβ 1-40 and therefore cause a shift in the Aβ 1-42 /Aβ 1-40 ratio, leading to higher concentrations of aggregation-prone Aβ . The binding affinity results, as well as the predominant importance of LRP1 at elevated Aβ concentrations, support the idea that maintaining steady Aβ clearance at the BBB by LRP1 could be a potential target for treatment of agerelated neurological disorders (51) .
We are aware that there are conflicting findings on LRP1 in previous studies. These results might be due to Aβ injections at concentrations beyond physiological relevance into different brain regions (17, 18, 52) or the use of epithelial cells, such as MDCK and CHO cells (5, 19) , for in vitro studies. Cell-specific functions of receptors have been reported for other members of the LDLR family (53) , so the function of LRP1 might be dependent on cell type and polarization state, as suggested before (21, 32) . Here, in the two BBB-specific knockout mouse models of Lrp1, we can positively say that the expression of LRP1 in brain endothelial cells strongly modulates soluble brain Aβ levels. Aβ and Aβ are the prevalent Aβ species found in amyloid plaques. In 7-month-old 5xFAD mice, we could not detect any significant differences in plaque deposition or gliosis when impairing a major Aβ elimination pathway through brain endothelial-specific deletion of Lrp1. However, absence of LRP1 in brain endothelium had striking effects on the concentrations of soluble Aβ species in the brain and resulted in significant cognitive deficits. As recent works suggest, the concentrations of soluble Aβ species, not the presence of plaques, seem to strongly correlate with the cognitive deficits in mouse models (54) and AD pathology in patients (55, 56) . In their study with 19 patients with AD and 18 controls, McLean and colleagues discovered that insoluble Aβ in humans appeared only to signify the presence of AD and that soluble Aβ concentrations seemed to correlate with the severity of disease. Moreover, their data on patients with AD showed a higher proportion of Aβ in the soluble fractions, possibly representing an intracellular and more neurotoxic pool of Aβ (55) . In the AD mouse model, we could observe similar effects. Deleting Lrp1 in brain endothelium severely increased soluble Aβ levels and elevated the Aβ 1-42 /Aβ 1-40 ratio. This led to severe effects on cognitive function, supporting the idea that soluble Aβ, but not plaque-bound Aβ, correlates with AD-related symptoms.
It has been shown that LRP1 is required for APP trafficking and Aβ production. Inhibition of LRP1 in cultured cells has been shown to significant reduce Aβ production (57) . In the 5xFAD model, these findings contradict the soluble Aβ accumulation that we observed in 5xFAD Lrp1 BE -/-mice. However, much of the Aβ in the brain is produced by neurons in which there is both high APP and LRP1 expression. LRP1 expression in neurons is not affected in this mouse model. The knockout of Lrp1 is restricted to brain endothelium and choroid plexus epithelium. As endothelial cells constitute only 1% to 2% of all cells in the brain (58), we do not believe that in 5xFAD Lrp1 BE -/-mice there is a significant effect on APP trafficking and overall Aβ production in the brain, compared with that in 5xFAD Lrp1 BE fl/fl mice. Additionally, the results taken from the Aβ in vivo injection experiments in Lrp1 BE -/-mice are mirrored by these from the 5xFAD mice crossed into the Lrp1 BE -/-background. Therefore, we assume that the role of Aβ production in this paradigm is minimal.
In conclusion, the data gathered with the brain endothelial-specific Lrp1 knockout mouse model prove that LRP1 in brain vasculature plays a key role in regulating brain Aβ levels. Although there are additional methods of Aβ clearance (6, 7, 38, 39), our and other data show that vascular transport across the BBB is of crucial importance for rapid Aβ elimination from brain (8, 11, 15) . Recent reports have identified different targets and strategies to restore and promote Aβ clearance at the BBB (16, 33, 59) . As LRP1 levels decrease with aging and in AD, maintaining the function of Aβ transporters could be a potential strategy for treatment and prevention of AD. and Aβ x-42 levels in 7-month-old 5xFAD Lrp1 BE -/-mice. n = 12, n = 5, n = 12, n = 5 (L) and n = 10, n = 5, n = 12, n = 5 (M) from left to right. Data represent mean ± SEM of n = 5. All samples except for those shown in lanes 1 and 2 in C were analyzed on the same Western blot but rearranged for clearer presentation. A shorter exposure is shown for Aβ and Aβ 1-42 standards in A. For statistical analyses, unpaired t test was used. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar: 200 μm. jci.org Volume 126 Number 1 January 2016 bovine serum (First Link), 100 U/ml penicillin (Gibco), 100 μg/ml streptomycin (Gibco), 2 mM l-glutamine (Gibco), 4 μg/ml puromycin (Alexis), and 1 ng/ml FGF (R&D Systems) at 37°C and 5% CO 2 . Cells were cultured in the cellZscope device, in which transendothelial electrical resistance (TEER) and capacitance were monitored over time. Puromycin was withdrawn after 4 days in culture. When cells reached confluency and the capacitance was around 1 μF/cm 2 , culture medium was removed and serum-free DMEM/Ham's F12 (Gibco) medium containing 1 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin was added. 550 nM hydrocortisone (Sigma-Aldrich) was supplemented to induce high TEER. The following day transport studies were performed. To analyze the efficiency of the tamoxifen-induced gene excision on DNA level, PCR analysis was performed using a PCR strategy with 3 primers to simultaneously detect WT, loxP flanked, and deleted Lrp1 alleles (26) . Genomic DNA was extracted from isolated primary cortical brain endothelial cells with the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich) according to the manufacture's protocol. Three primers (A, 5′-TGGGATGAGGTAGACGCAGT-3′; B, 5′-CCTGGAGAAC-GTTCCAGTTC-3′; C, 5′-CCTGGAGAACGTTCCAGTTC-3′) were simultaneously used in one PCR reaction to investigate the efficiency well-established AD model that harbors 3 APP mutations and 2 presenilin 1 mutations that are linked to FAD. Primers for genotyping are as follows: Lrp1-fwd, 5′-CATACCCTCTTCAAACCCCTTCCTG-3′ and Lrp1-rev, 5′-GCAAGCTCTCCTGCTCAGACCTGGA-3′ for loxP, Cre-fwd, 5′-GCTATTCATGTCTTGGAAGCC-3′ and Cre-rev, 5′-CAGGTTCTTCCTGACTTCATC-3′ for Cre; and 5xFAD-fwd 5′-CATGACCTGGGACATTCTC-3′ and 5xFAD-rev 5′-GTAGCAGAG-GAGGAAGAAGTG-3′ for the 5xFAD site. Mice were housed on a 12-hour-light cycle. Unless stated otherwise, the animals had ad libitum access to water and a standard laboratory diet. In all experiments, littermates harboring (Lrp1 BE -/-) or lacking (Lrp1 BE fl/fl ) the Cre allele were used. In order to induce recombination, 4-to 11-week-old mice were injected i.p. with 2 mg tamoxifen (T5648, Sigma-Aldrich) for 5 to 7 consecutive days. The analysis of recombination was examined 3 days after the last treatment. Lrp1 BE fl/fl control animals were treated equally.
To maintain Cre-mediated recombination over time, 7-month-old animals were fed chow supplemented with 400 mg tamoxifen citrate per kilogram dry weight (CRE Active TAM400, LASvendi).
Reagents and antibodies.
[ Table 1 .
Isolation of primary mouse brain capillary endothelial cells. Primary mouse brain capillary endothelial cells were isolated from 8-to 12-week-old littermate mice according to a standard protocol as described previously (32, 34) . Cells were plated on 24-well Transwell filters (pore size, 0.4 μm; surface area, 33.6 mm 2 ; Greiner BioOne) coated with collagen IV/fibronectin (Sigma-Aldrich). Cultures were maintained in DMEM supplemented with 20% plasma-derived 10 μg/ml Na-fluorescein in 1:1 Tris-HCl/methanol (v/v) were added to each plate. The intensity of fluorescence was read at λ = 519 nm (excitation, 488 nm).
In vitro transcytosis of [
125 I] Aβ . In order to study Aβ transcytosis in vitro, a standard transport model was used (5, 32, 34) . Brain efflux index method. A standard method was used to quantify brain-to-blood efflux rates (8, 11, 61) . A stainless steel cannula was stereotaxically implanted into the right caudate putamen of age-and sex-matched mice that had been anesthetized with ketamine (800 mg/kg) and medetomidine (5 mg/kg). The cannula tip coordinates were as follows: 0.9 mm anterior from bregma, 1.9 mm lateral from midline, and 2.9 mm below the surface. Before injection of tracer molecules, animals recovered for 4 to 6 hours, a time point that precedes the start of the substantial inflammatory process, as assessed by histological analysis of tissue (negative staining for reactive astrocytes [GFAP] and reactive microglia [antiphosphotyrosine]), but allows partial BBB repair for large molecules, as reported previously (15, 61 CSF isolation. 15 minutes after injection of tracers, as described above, 3.5-to 12-μl samples of CSF were taken from animals via cisterna magna puncture, as reported elsewhere (62) , and used for radioactive analysis.
Calculation of in vivo [ As previously reported, there are two major methods of Aβ elimination: direct transport across the BBB into the bloodstream and bulk of the Cre-mediated recombination with regard to to the length of the different amplified products. Primers were designed to amplify a 541-bp product for the unexcised allele containing the loxP site, a 507-bp product for the WT allele, and a 325-bp product for the excised allele after Cre recombinase-catalyzed recombination.
Capillary depletion. Capillary-depleted brain homogenates were prepared as described elsewhere, using dextran density gradient centrifugation to separate microvessels from total brain homogenates (60 centrifuged at 55,000 g for 20 minutes at 4°C. Supernatants, containing insoluble plaque-associated Aβ, were immediately frozen at -80°C. The levels of Aβ x-40 and Aβ x-42 peptides in brain extractions were blindly determined using a cell-based sandwich ELISA assay as described previously (63) .
Immunoprecipitation of Aβ. Total Aβ was immunoprecipitated from blinded samples of blood serum and soluble and insoluble brain pools by mixing 5-fold concentrated detergent buffer (50 
Measurement of Aβ species by ELISA.
Brains were weighed and subjected to a sequential Aβ extraction. Then, brains were homogenized in PBS containing complete protease and phosphatase inhibitor (Roche Applied Science) using a glass homogenizer and subsequently centrifuged at 55,000 g for 20 minutes at 4°C. The supernatant, containing soluble brain Aβ, was removed and stored at -80°C. Then, the pellet was dissolved in 2% SDS in PBS containing complete protease and phosphatase inhibitor, sonificated, incubated for 30 minutes on ice, and Figure 10 . Deletion of Lrp1 in brain endothelial cells leads to cognitive deficits in 5xFAD Lrp1 BE -/-mice. 7-month-old female 5xFAD Lrp1 BE -/-(n = 5), 5xFAD Lrp1 BE fl/fl (n = 7), Lrp1 BE -/-(n = 5), and WT (n = 6) control mice were tested. (A) Animals underwent acquisition training to learn to use proximal and distal cues to navigate a path to a hidden platform. A significant difference in the escape latency of 5xFAD Lrp1 BE -/-mice compared with that of all other groups was seen on days 3 to 5. (B and E) Swimming speed was not affected in all mice tested. (C) Spatial reference memory deficits in 5xFAD Lrp1 BE -/-mice were shown in the probe trial, in which 5xFAD Lrp1 BE -/-mice spent significantly less time in the target quadrant than all other groups of mice. The probe trial was given after the acquisition training phase to assess spatial reference memory. (D) 5xFAD Lrp1 BE fl/fl mice showed no impairment of spatial reference memory, as reflected by the significant greater percentage of time spent in the target quadrant (P < 0.001 target vs. left, right, and opposite quadrant). The probe trial revealed a significant impairment of spatial reference memory in 5xFAD Lrp1 BE -/-mice, as they showed no preference for the target quadrant. T, target quadrant; L, left quadrant; R, right quadrant; O, opposite quadrant. Data represent mean ± SEM. For statistical analyses, the following test was used: repeated-measures ANOVA followed by Bonferroni multiple comparisons. *P < 0.05, ***P < 0.001.
